Biofrontera Inc. reports news on the commercialization and development of photodynamic therapy in dermatology. The company’s core product platform includes Ameluz, an aminolevulinic acid hydrochloride topical gel used with the RhodoLED red-light lamp series, with an established focus on actinic keratoses and clinical programs addressing additional dermatologic conditions.
Recurring updates include financial results, U.S. commercial performance, clinical data for Ameluz PDT, FDA-related label-expansion activity, patent proceedings, and business updates tied to the company’s U.S. product rights, regulatory approvals, intellectual property, and manufacturing rights.
Biofrontera announced a securities purchase agreement with an institutional investor for 2,857,143 shares and warrants to purchase an equal number of shares at a price of $5.25 per share. This private placement is expected to generate approximately $15 million in gross proceeds, closing on or about December 1, 2021. The warrants are immediately exercisable and will expire in five years. The company must file a registration statement with the SEC within 15 days to cover the resale of these securities.
Biofrontera Inc. (Nasdaq: BFRI) will announce its financial results for the three and nine months ending September 30, 2021, before the U.S. markets open on November 30, 2021. The company will host a conference call that day at 4:30 p.m. Eastern time to discuss the results and provide a business update. Biofrontera specializes in dermatological products and focuses on treating conditions such as actinic keratoses and impetigo. Investors can access the live webcast and replay on their website.
Biofrontera Inc. (BFRI) has initiated a clinical study program to optimize its FDA-approved drug, Ameluz®, for photodynamic therapy in the U.S. Two studies are set to begin recruiting patients before year-end, focusing on treating moderate-to-severe acne and assessing safety with multiple tubes of Ameluz®. Under a licensing agreement with Biofrontera AG, the company holds exclusive marketing rights. Ameluz® is crucial for Biofrontera's growth in the U.S. dermatological market, aiming to enhance its positioning against actinic keratosis.
Biofrontera Inc. announced the closing of its initial public offering on November 2, 2021, raising $18 million by issuing 3,600,000 units, each comprising one common share and one warrant, priced at $5.00 per unit. The offering was successful, with underwriters exercising an option for an additional 540,000 warrants. These warrants are exercisable over five years at the same price. Biofrontera's common stock and warrants trade under the symbols BFRI and BFRIW respectively.
Biofrontera Inc. (Nasdaq: BFRI) announced its initial public offering (IPO) of 3,600,000 units, each priced at $5.00, consisting of one share of common stock and one warrant. The offering could generate $18 million in gross proceeds, before deducting fees. A 30-day option allows underwriters to purchase an additional 540,000 shares. Trading for these securities is set to start on October 29, 2021, with the offering closing expected on November 2, 2021.